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Abstract
Introduction: Increasing antimicrobial costs, reduced development of novel antimicrobials, and growing
antimicrobial resistance necessitate judicious use of available agents. Antimicrobial stewardship programs (ASPs)
may improve antimicrobial use in intensive care units (ICUs). Our objective was to determine whether the
introduction of an ASP in an ICU altered the decision to treat cultures from sterile sites compared with nonsterile
sites (which may represent colonization or contamination). We also sought to determine whether ASP education
improved documentation of antimicrobial use, including an explicit statement of antimicrobial regimen, indication,
duration, and de-escalation.
Methods: We retrospectively analyzed consecutive patients with positive bacterial cultures admitted to a 16-bed
medical-surgical ICU over 2-month periods before and after ASP introduction (April through May 2008 and 2009,
respectively). We evaluated the antimicrobial treatment of positive sterile- versus nonsterile-site cultures, specified a
priori. We reviewed patient charts for clinician documentation of three specific details regarding antimicrobials: an
explicit statement of antimicrobial regimen/indication, duration, and de-escalation. We also analyzed cost and
defined daily doses (DDDs) (a World Health Organization (WHO) standardized metric of use) before and after ASP.
Results: Patient demographic data between the pre-ASP (n = 139) and post-ASP (n = 130) periods were similar.
No difference was found in the percentage of positive cultures from sterile sites between the pre-ASP period and
post-ASP period (44.9% versus 40.2%; P = 0.401). A significant increase was noted in the treatment of sterile-site
cultures after ASP (64% versus 83%; P = 0.01) and a reduction in the treatment of nonsterile-site cultures (71%
versus 46%; P = 0.0002). These differences were statistically significant when treatment decisions were analyzed
both at an individual patient level and at an individual culture level. Increased explicit antimicrobial regimen
documentation was observed after ASP (26% versus 71%; P < 0.0001). Also observed were increases in formally
documented stop dates (53% versus 71%; P < 0.0001), regimen de-escalation (15% versus 23%; P = 0.026), and an
overall reduction in cost and mean DDDs after ASP implementation.
Conclusions: Introduction of an ASP in the ICU was associated with improved microbiologically targeted therapy
based on sterile or nonsterile cultures and improved documentation of antimicrobial use in the medical record.
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Introduction
Antimicrobial use in the intensive care unit (ICU) is see-
mingly ubiquitous. An international, prospective, point
prevalence study of more than 1,200 ICUs documented
that 71% of ICU patients received antimicrobials [1].
This widespread use may be inappropriate, with recent
studies estimating as many as 30% of regimens are
unnecessary [2-5]. The consequences of unnecessary
antimicrobial use (antimicrobial resistance, adverse
events, and cost) necessitate judicious use.
Antimicrobial stewardship programs (ASPs) represent
organizational approaches to harmonize competing con-
cerns of adequate antimicrobial coverage, adverse events,
and resistance, and are well suited to ICU settings [4,6]. A
position statement from the Infectious Disease Society of
America (IDSA), the Society for Healthcare Epidemiology
of America (SHEA), and the Pediatric Infectious Disease
Society (PIDS), deemed stewardship a “fiduciary responsi-
bility for all healthcare institutions” and recommended
mandatory implementation [7].
In critically ill patients, one study documents up to 50%
of positive cultures may actually represent contamination
[8]. Positive microbial cultures in critically ill patients
often prompt reflexive antimicrobial therapy, regardless
of the sampling site or the contamination potential [8].
Specifically, positive “sterile site” cultures (such as blood
cultures) better represent true infection than do positive
“nonsterile site” cultures (such as wound cultures). Non-
sterile sites are more likely to reflect colonization or con-
tamination. Appropriate antimicrobial use should
preferentially treat positive cultures from sterile sites
rather than from nonsterile sites. Distinguishing between
contamination and true positives can be difficult [8], and
clinicians may benefit from ASP assistance with regimen
choice and education surrounding contamination
potential.
Although the literature suggests that ASPs are associated
with reduced ICU antimicrobial utilization [7], how these
results are achieved on an individual patient level is
unclear. Our objective was to determine whether the
introduction of an ASP in a medical-surgical ICU altered
the decision to treat positive sterile versus nonsterile cul-
ture sites. The IDSA/SHEA/PIDS consensus statement [7]
recommends “address[ing] deficiencies in education” to
improve antimicrobial practice. We developed an inter-
vention of academic detailing by our ASP during medical-
surgical ICU rounds. We hypothesized that this interven-
tion would alter provider decisions to treat positive sterile
versus nonsterile culture sites and that an improved
understanding would be manifest in higher quality docu-
mentation of antibiotic decisions.
A previous study examined videotaped recordings of
resident/patient encounters and medical documentation
[9]. This study demonstrated that residents in their
second year produced better documentation than did
first-year residents. This study inferred that knowledge
and experiential teaching play a role in chart-documen-
tation practices [9]. Another study by Carroll et al. [10]
demonstrates that daily progress notes written by resi-
dent physicians in the neonatal ICU often contain inac-
curate, or omit, pertinent information. Documentation
inaccuracy or omission usually surrounds items that
residents feel uncomfortable managing; such as vascular
lines and medications. We postulate that our educa-
tional ASP may help to chart better documentation
practices by discussing antimicrobial status with an
infectious disease physician and/or pharmacist.
Inappropriate overuse results from inappropriate assess-
ment of risk, incorrect utilization and/or interpretation of
tests suggesting infection (for example, white blood cell
count), and prolonged duration of therapy. By suggesting
to physicians, for example, that isolated leukocytosis is not
an indication for “panculturing” or that wound swabs are




A quasi-experimental uncontrolled intervention was used
to determine the impact of an ASP on the treatment of
positive sterile-site compared with nonsterile-site cul-
tures. The institution’s Research Ethics Board approved
this study and waived the need for informed consent,
given the retrospective design.
Patients
We reviewed consecutive patients older than 18 years,
who were admitted to the ICU, had positive microbial
cultures, and received antimicrobials. The first group of
patients was admitted to the ICU during April and May
2008 and represented the pre-ASP period, and a second
group of patients admitted during April and May 2009
represented ICU practices after ASP introduction. The 2-
month period was used as a convenience sample. The
ASP was introduced to the institution in February 2009,
and we selected April/May 2008 and 2009 for data collec-
tion to allow maturation of the intervention as well as to
control temporal and seasonal effects.
Setting
Mount Sinai Hospital is a 472-bed teaching hospital
affiliated with the University of Toronto. The medical-sur-
gical ICU is a closed unit, with 16 active beds and staff
intensivists, fellows, residents, a dedicated ICU pharmacist,
and other allied health personnel. The ICU occupancy in
2008 and 2009 was 82% and 80%, respectively. Approxi-
mately 13% of bed occupancy involves patients with hema-
tologic malignancies.
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Intervention
Our ASP approach centered on education, expert consul-
tation, prospective audit, and feedback [11]. The ASP
team, which included a dedicated ASP pharmacist and an
infectious disease consultant, interacted with prescribers
in a collaborative and educational capacity. The ASP
aimed to curtail unnecessary use by engaging the prescri-
ber in frequent, scheduled, face-to-face clinical-decision
support, in the setting of minimal electronic decision-sup-
port tool availability. Each weekday, the ASP team met
with the ICU team after routine ICU rounds, and reviewed
each ICU patient. Recommendations for individual
patients were based on clinical, radiographic, and labora-
tory data, including microbiology results. Recommenda-
tions were made for further investigations, antimicrobial
agents, de-escalation, and the need for formal infectious-
disease consultation (a routine consultation service super-
vised by an attending infectious-disease staff physician).
The ICU team was free to consult the infectious-disease
service as they saw fit, and compliance to the infectious-
disease team was not recorded. Similarly, adherence to the
ASP team recommendations (which is separate from the
infectious-disease team, although also led by an infectious-
disease physician) was optional for the ICU team. The
face-to-face interaction between ASP and ICU team took
approximately 1 minute per patient per day.
Data collection
Data were collected retrospectively from the patient’s
paper and electronic charts. Parameters collected included
demographic data, culture results, antimicrobial regimen,
ICU chart documentation practices, cost, and defined
daily doses (DDDs) per 1,000 patient-days. Culture results
were recorded and stratified into sterile and nonsterile
sites, specified a priori. Sterile sites included blood cul-
tures, bronchoalveolar lavage (BAL), pleural fluid, cere-
brospinal fluid, peritoneal fluid, bile, pancreatic fluid, and
muscle tissue. Nonsterile sites included sputum, nasophar-
yngeal swabs, urine, wound, nail, skin, stool, genital swabs,
rectal swabs, and gastric aspirates.
Patient charts were reviewed by one reviewer, CK, for
standardization. The reviewer was blinded during data
abstraction. The daily ICU progress notes were analyzed
exclusively for details surrounding documentation. The
daily ICU notes are written each day for the patients’
length of stay in the ICU. A binary yes/no decision for
“appropriate documentation” was made for each daily pro-
gress note independently. The percentage of appropriate
documentation was calculated with the number of appro-
priately documented daily ICU notes divided by the total
daily ICU notes. The daily progress notes were chosen in
lieu of the nursing Kardex, nursing notes, pharmacist
notes, or daily prescription as a measure of medical-lear-
ner behavioral change, one of the cited areas of deficiency
in the recent IDSA/SHEA/PIDS consensus statement on
ASPs [7]. Charts were reviewed for documentation of
three specific details: (a) regimen and indication, (b) dura-
tion, and (c) de-escalation. These parameters were col-
lected as binary “yes/no” data points ("yes” deemed
optimal documentation, and “no” deemed inappropriate
documentation or the absence of documentation).
Documentation of regimen/indication was defined as
the documentation of antimicrobial agent by name and
indication (for example, ceftriaxone, 2 g IV, for sus-
pected meningitis). The abbreviated documentation of
“on antibiotics” was deemed inappropriate documenta-
tion. Charts were deemed to have “no documentation”
when the antimicrobial agent was not overtly documen-
ted, infectious-disease section of daily note omitted, or
when the indication was not explicit.
Antimicrobial duration was defined as explicit start and
stop dates for antimicrobial regimens, or specific duration
of therapy (for example, 3 days). Documentation was
deemed adequate if the criteria for appropriate regimen/
indication were also met. The abbreviated documentation
of “2-week course” without an explicitly named antimicro-
bial agent or indication was deemed inappropriate docu-
mentation. We chose to define this parameter in this
manner as a teaching point for junior learners; for exam-
ple, if the learner consistently documents “trimethoprim/
sulfamethoxazole, 160 mg PO BID, for 3 days for uncom-
plicated urinary tract infection,” the learner is more likely
to learn and remember duration and indication. The per-
centage of appropriate documentation was calculated by
the number of daily ICU notes fulfilling the definition of
appropriate regimen/indication documentation and appro-
priate duration documentation divided by the number ful-
filling the definition of appropriate regimen/indication.
De-escalation of antimicrobial therapy was defined as
parenteral-to-enteral route exchange, agent exchange to
tailor spectrum of activity (based on culture results),
and discontinuation of unnecessary agents, as per prior
definition in the literature [5]. Documentation was
deemed adequate if the criteria for appropriate regimen/
indication were met in addition to de-escalation details.
The abbreviated documentation of “antibiotics tailored,”
“antibiotics de-escalated,” or “cultures specified, antibio-
tics changed” without any other specifics were deemed
inappropriate documentation. The percentage of appro-
priate documentation was calculated by the number of
daily ICU notes fulfilling appropriate regimen/indication
definition and de-escalation definition divided by the
number fulfilling the regimen/indication definition.
The ASP team did not contribute to medical records,
and thus, did not contribute to better chart documentation
practices.
Decisions regarding treatment of positive nonsterile
cultures and a clinical picture consistent with an
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infection in that organ system was at the discretion of
the treating ICU physician and is a tenet of ASP rounds.
The ASP team may suggest that the culture represents
contamination, but if the clinical picture is one of infec-
tion, the ICU team may disregard ASP suggestions,
thereby preserving ICU prescribing autonomy.
Our study did not address the issue of prescribing anti-
microbials before cultures are drawn as the Surviving
Sepsis guidelines [12] advocate for the initiation of
broad-spectrum antibiotics followed by appropriate de-
escalation. We sought to examine the ASP influence on
ICU prescribing practices based on culture site only after
the final culture report was returned. For example,
empiric antimicrobials that were continued after positive
nonsterile culture results returned were deemed “treated
nonsterile culture sites.” Likewise, empiric antimicrobials
that were stopped when culture results returned were
counted as “nontreated.”
We sought to examine use of antimicrobials before and
after ASP, and used DDD as our metric. DDDs are defined
by the World Health Organization (WHO) as the assumed
average maintenance dose per day for a medication used
for its main indication in adults [13]. The DDD is assigned
by the WHO for medications that have a WHO Anatomi-
cal Therapeutic Chemical code. The DDD is a unit of
measure that may not necessarily reflect the recom-
mended or prescribed daily dose. DDDs provide estimates
of drug consumption independent of cost [13]. We use the
DDD to assess the trends in drug consumption and to per-
form comparisons between groups, as recommended by
the WHO [13]. DDDs were calculated monthly based on
dispensing data from the pharmacy system (PharmaNet
Inpatient, Cerner Corporation, Kansas City, MO, USA).
To calculate DDDs, the dispensed antimicrobial quantity
(in grams) was divided by the WHO DDD. This result was
then divided by the ICU patient days and then multiplied
by 1,000 to obtain DDDs/1,000 patient days as a standar-
dized metric. Costs of antimicrobials dispensed were
obtained from reports by using the Pharmacy Depart-
ment’s PharmaNet pharmacy software (PharmaNet Devel-
opment Group, Princeton, NJ, USA) and are reported in
Canadian dollars. All costs over the 2-month period of
April and May 2008 and 2009, respectively, were summed
to give a total cost of antimicrobials. Antimicrobial costs
were also calculated per patient-day in the ICU. Costs and
DDD data will be presented as descriptive statistics, as
they are not a primary outcome of this study. Costs of
antimicrobials were not standardized; however, they did
not change significantly within the 2-year period of the
study.
Statistical analysis
Regimens by sample-site sterility and ICU documenta-
tion practices were analyzed by using the c2 test, with
one degree of freedom and Yates continuity correction.
Descriptive statistics such as absolute percentage
decreases or increases over the study time period were
used to analyze cost and DDDs. As a measure of quality
improvement, we calculated a novel measure, the Sam-
ple Sterility Ratio (SSR, which is the ratio of sterile-site
samples treated to nonsterile-site samples treated), and
followed this metric to document treatment effect over
time. We calculated a percentage for chart documenta-
tion in each of the three parameters (antimicrobial regi-
men/indication, duration, and de-escalation). Microsoft
Excel (Microsoft Corp., Redmond, WA, USA) was used
for analysis. A P < 0.05 was considered significant.
Results
In total, 269 patients were admitted to the medical-surgi-
cal ICU during the 2-month pre-ASP period (n = 139) and
the 2-month post-ASP period (n = 130) requiring antimi-
crobials. Demographics of the pre-ASP and post-ASP
groups were similar (Table 1). A statistically significant
increase was found in the number of formal infectious dis-
ease consultations after ASP (nine versus 22; P = 0.013).
Before ASP, 225 positive cultures were used versus
179 after ASP. The number of sterile cultures was simi-
lar between the pre-ASP period and post-ASP period
(101 versus 72; P = 0.401) (Table 2). The number of cul-
tures by culture type was similar between the pre- and
post-ASP periods, except for a significant increase in the
number of positive sputum cultures in the post-ASP
period (38 versus 48; P = 0.036)
A higher proportion of sterile-site cultures was treated
after ASP (64% versus 83%; P = 0.01), and a lower










Male 62 (45%) 67 (52%) 0.310
Older than 70 years 50 (36%) 42 (32%) 0.614
Medical admission 89 (64%) 90 (69%) 0.439
Transferred from external institution 44 (32%) 52 (40%) 0.194
APACHE II (mean ± SD) 21.9 ± 6.2 22.6 ± 5.2 0.318
Malignancy 42 (30%) 30 (23%) 0.237
Previous HSCT 2 (1%) 8 (6%) 0.085
Renal replacement therapy 13 (9%) 13 (10%) 0.858
Infectious Disease Service
consultations
9 (7%) 22 (17%) 0.013
ICU mortality 26 (19%) 18 (13%) 0.362
Malignancy, active malignancy (cancer within in past 6 months, or currently
receiving treatment such as radiation or chemotherapy) or malignancy within
10 years before admission; HSCT, hematopoietic stem cell transplant (defined
as autologous or allogenic stem cell transplantation within the past 5 years
and includes both myeloablative and nonmyeloablative transplant protocols);
renal replacement therapy, all forms of dialysis (intermittent hemodialysis,
continuous renal replacement therapy, and so on).
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proportion of nonsterile-site cultures was treated (71%
versus 46%; P = 0.0002). The majority of untreated ster-
ile cultures were coagulase-negative staphylococci in
blood cultures or positive BAL cultures, likely represent-
ing contaminants.
We repeated the analysis as a per-patient-based analy-
sis as well as a per-culture-based analysis. This was
done because we identified patients who had only posi-
tive sterile-site cultures, others who had only positive
nonsterile-site cultures, and a group that had both posi-
tive sterile-site and positive nonsterile-site cultures. In
the per-patient-based analysis, a higher proportion of
patients with only positive sterile-site cultures were trea-
ted after ASP (70% versus 91%; P = 0.0082) and a lower
proportion of patients with only nonsterile-site cultures
were treated after ASP (94% versus 48%; P = 0.0001).
No statistical difference was found in treating patients
who had both positive sterile- and nonsterile-site cul-
tures after ASP (67% versus 42%; P = 0.3632) (Table 3).
Statistically significant results were also found when the
analysis was repeated as a per-culture-based analysis. A
higher proportion of the cultures from patients with only
positive sterile-site cultures were treated after ASP (61%
versus 90%; P = 0.0002) and a lower proportion of the cul-
tures from patients with only nonsterile-site cultures were
treated after ASP (89% versus 47%; P = 0.0001). No statis-
tical difference was found in treating cultures from
patients who had both positive sterile- and nonsterile-site
cultures after ASP (52% versus 44%; P = 0.6139; Table 4).
Increasingly detailed ICU chart documentation was
available after ASP. A higher proportion of charts detailed
antimicrobial regimen/indication after ASP (26% versus
71%; P < 0.0001). After ASP, an 18% absolute increase
(53% versus 71%; P < 0.0001) was found in the number of
regimens with formally documented stop dates and a sig-
nificant increase in de-escalation of antimicrobials (15%
versus 23%; P = 0.026).
The Sample Sterility Ratio increased from 0.9 before
ASP to 1.54 after ASP. Treated cultures before and after
ASP implementation are graphically detailed in Figure 1,
separated by culture designation.
ICU antimicrobial costs decreased in the post-ASP
period ($60,610 before ASP versus $43,857 after ASP)
(Table 5). No appreciable changes in drug acquisition
costs were found for the hospital over the study period.
Antimicrobial use was 13.7% higher in the pre-ASP per-
iod compared with the post-ASP period (3,592 versus
3,010 DDD/1,000 patient days) (Table 5).
Discussion
After the introduction of ASP, we observed a statistically
significant increase in the treatment of sterile-site cul-
tures and a reduction in the treatment of nonsterile-site
cultures, in both our per-patient and per-culture-based
analyses. Increasingly detailed chart documentation was
observed after ASP, with an increase in formally docu-
mented stop dates, as well as reductions in antimicrobial
use and costs after ASP implementation. We calculated
a novel measure, the Sample Sterility Ratio, which was
increased after ASP.
Multiple studies report benefits of ASP implementation,
demonstrated in both hospital patients and critically ill
patients [4,6,7]. No literature reports detail treatment
choice by culture site, or ICU chart documentation after
ASP. To our knowledge, this is the only study to docu-
ment the change in processes of care that accompany the
introduction of an ASP in the ICU: improved documenta-
tion of antimicrobial therapy and more judicious attention
to the quality and sterility of positive microbiologic sam-
ples. Only one other study in the literature examines chart
documentation in the ICU [14]. This prospective before
and after 7-month intervention study in a medical ICU in
Table 2 Distribution of positive sterile and nonsterile
cultures
Before ASP After ASP P value
Sterile cultures 101 72
Blood 70 (69%) 55 (76%) 0.394
Othera 31 (31%) 17 (24%) 0.394
Nonsterile cultures 124 107
Sputum 38 (31%) 48 (45%) 0.036
Urine 44 (35%) 36 (34%) 0.877
Wound 25 (20%) 14 (13%) 0.209
Otherb 17 (14%) 9 (8%) 0.288
aIncludes pleural fluid, pancreatic fluid, bronchoalveolar lavage, and muscle
tissue. bIncludes arterial and venous catheter tips, skin, and rectal cultures.
Table 3 Treatment of sterile versus nonsterile sites: per patient analysis
Before ASP After ASP P value
Patients 139 130
Patients with only positive sterile cultures 71 56
Patients treated 50 (70%) 51 (91%) 0.0082
Patients with both positive sterile and positive nonsterile cultures 15 12
Patients treated 10 (67%) 5 (42%) 0.3632
Patients with only positive nonsterile cultures 53 62
Patients treated 50 (94%) 30 (48%) 0.0001
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France documented similar findings to those of our study,
increased reassessment of antimicrobial prescriptions after
the intervention [14].
A few studies detail educational relations between the
ASP and ICU teams. Our results may have considerable
merit to hospital administrators, who may consider ASP
implementation as a cohesive approach of instituting bet-
ter antimicrobial practices. The IDSA/SHEA/PIDS policy
statement warns against the “rapidly dwindling antimi-
crobial armamentarium” and names ASPs “fiduciary
responsibilities for all healthcare institutions” [7]. They
recommend the “creation of a multidisciplinary interpro-
fessional team” similar in structure to our intervention
[7]. The guidelines state that
significant knowledge deficits in the areas of antimicro-
bial stewardship are prevalent....and that educational pro-
grams should be developed...because of the gravity of the
problems with antimicrobial resistance that confront
society and the paucity of readily available clinical solu-
tions [7].
Strengths of our study include the attention to prescri-
ber education in the ASP structure. Education is widely
considered the foundation of a successful ASP [7,9] yet a
paucity of dedicated evidence supports this assertion.
The optimal constituents of a mutually beneficial educa-
tional ASP program are unknown. Our ASP educates
prescribers directly at the point of care, as well as
through audit and feedback. Our strategy facilitates
change on a case-by-case basis, and we here demonstrate
that this strategy produces measurable change in both
process and outcomes related to antimicrobial prescrib-
ing (antimicrobial use by culture site, chart documenta-
tion, cost, and use).
Another strength of our study is the statistically signif-
icant findings of increased treatment of sterile-site cul-
tures and decreased treatment of nonsterile-site cultures
in both a per-patient and a per-culture analysis. We
believe the consistent statistical significance in both ana-
lyses demonstrates the rigor of our methods.
Another strength of our study includes a quantification
of better chart-documentation practices after ASP. A pre-
vious study demonstrated that antimicrobial indication
was recorded in 64% of patients before feedback and in
86.5% after feedback (P = 0.004) [15]. Our findings indi-
cate a similar change. This is important because senior
consultation advice and pertinent clinical infectious signs
are rarely recorded [15], making indication sometimes
difficult to elucidate in the daily ICU note. Without
transparent chart documentation, it becomes increasingly
difficult for other clinicians to make informed decisions.
In an academic ICU setting with multiple consultants
and high turnover of relatively junior housestaff, better
documentation improves communication and may
increase patient safety.
Our study has limitations. It is a single-center, uncon-
trolled, quasi-experimental study. Our data may reflect
local prescription bias, formulary contracts, patient
demographics, and ICU culture unique to our center,
which may limit generalizability. Our data may also
reflect a unique ASP relationship with the ICU team,
which may not be replicable. In addition, our 2-month
data may not reflect long-term practice or demonstrate
durability of effect. However, the study results are
Table 4 Treatment of sterile versus nonsterile sites: per culture analysis
Before ASP After ASP P value
Positive cultures 225 179
Sterile 101 (45%) 72 (40%) 0.401
Nonsterile 124 (55%) 107 (60%) 0.401
Sterile cultures treated 65 (64%) 60 (83%) 0.01
Nonsterile cultures treated 88 (71%) 49 (46%) 0.0002
Number of cultures of patients with only positive sterile cultures 86 60
Cultures treated 52 (61%) 54 (90%) 0.0002
Number of cultures of patients with both positive sterile and positive nonsterile cultures 60 32
Cultures treated 31 (52%) 14 (44%) 0.6139
Number of cultures of patients with only positive nonsterile cultures 79 87
Cultures treated 70 (89%) 41 (47%) 0.0001
Figure 1 Treated cultures before and after ASP implementation
separated by culture designation.
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similar to those of other studies that demonstrate the
multiple benefits of an institutional ASP [5-7].
Another limitation of our study may be the choice of
counting daily progress notes for documentation purposes.
A number of areas in the patient’s chart may document
antimicrobial use (for example, doctor’s orders, sign-out
sheet). However, counting each of these as single docu-
mentation events would have been difficult logistically, so
we chose the daily progress notes (which are completed
on ICU team rounds and represent the team’s plan for the
patient for that day) as a representation of documentation,
noting that this may be incomplete.
Another limitation to our study may the classification
of bronchoalveolar lavage (BAL) as a “sterile” site. BALs
at our institution represent the “best” airway culture
site, as nasopharyngeal swabs and endotracheal aspirates
may have more-frequent contamination. We understand
that BALs have their own risk of potential contamina-
tion; however, we note that the American Thoracic
Society still endorses BAL diagnostic use for several
respiratory infections.
Another limitation may be the use of DDD as our metric
for pharmacologic outcomes. DDDs may underestimate
renal antimicrobial dosing (relevant in centers with a high
incidence of renal insufficiency) [16]. We have also intro-
duced a new metric, the SSR. This metric may be calcu-
lated and serially followed to document treatment effect;
however, it has not been prospectively validated.
Limited previous studies demonstrate measurable out-
comes without formulary restriction [17]. Considerable
attention is attributed to successful ASPs with formulary
restriction or preauthorization [17], and some may criti-
cize our ASP model for its lack of such methods. Formu-
lary restriction consists of decreased accessibility to
certain controlled antimicrobials. It is postulated that for-
mulary restriction will not change fervent prescriber
beliefs, and thus may not have consistent or sustained
impact on prescription patterns [4]. Additionally, formu-
lary restriction does not address: (a) the potential need
for source control; (b) the use of antimicrobials when
they are not indicated at all; (c) the occasional need for
broader/specific coverage; and (d) appropriate duration of
therapy. The most common consequence of formulary
restriction is “squeezing the balloon” (that is, by limiting
the use of one or several antimicrobial agents, other anti-
microbial use is inflated) [18,19]. We also believe it is an
onerous ASP intervention that requires additional per-
sonnel and is often more constabulary than collegial. It is
also perceived to diminish prescribing autonomy [4,20].
Although such programs are shown to decrease antimi-
crobial use, once the approval process is withdrawn, use
of the particular antimicrobial increases substantially
[20]. We have shown that with an ASP without formulary
restriction focused on education, formal review and face-
to-face clinical decision support can produce measurable
behavioral change. We believe this has a twofold benefit:
in the short term, to help the discussed patient, and in the
long term, benefit of education, which may change prac-
tice and prescriber culture. Previous audit and feedback
strategies vary and have produced inconsistent results.
We have tried to produce a more-effective feedback ASP
intervention by incorporating previously successful stra-
tegies in the literature [21-23] with our own nonrestricted
formulary based face-to-face decision support.
Ongoing evaluation is required to measure long-term
cost and patient-outcome implications of our ASP. Stu-
dies of prescriber and learner behavioral changes may
be carried out to ensure the longevity of better chart-
documentation practices and retention of appropriate
antimicrobial use.
Conclusions
Appropriate and judicious antimicrobial use guided by
an ASP can be associated with significant benefit in cri-
tically ill patients. ASPs guide the clinician, measure
adherence and performance, and ultimately benefit
patients. Our ASP team minimized unnecessary use by
sterile and nonsterile culture site, improved chart docu-
mentation, and decreased antimicrobial costs and overall
use. Our ASP may warrant consideration by other
teaching centers as a way to provide opportunities for
education and collaboration, to conserve prescriber
Table 5 Antimicrobial use, cost, and chart documentation
Before ASP After ASP Change {%}
DDD/1,000 patient days 3,592 3,100 -13.7
Antimicrobial costs $60,610 $43,866 -27
Antimicrobial costs/patient day $71 $54 -24
P value
Antimicrobial regimen and indication documentation 206/779 (26%) 467/662 (71%) <0.0001
Antimicrobial duration 109/206 (53%) 336/467 (71%) <0.0001
Antimicrobial de-escalation 31/206 (15%) 107/467 (23%) 0.026
DDD, Defined daily doses; costs, in Canadian dollars.
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autonomy, and ultimately to produce beneficial clinical
outcomes and enhance patient safety.
Key messages
• This type of antimicrobial stewardship model edu-
cates the prescriber directly at the point of care, as
well as through audit and feedback.
• This type of antimicrobial stewardship model does
not use formulary restriction and preserves prescri-
ber autonomy.
• A statistically significant increase was noted of
treating sterile-site cultures after ASP and treating
fewer nonsterile-site cultures, both by per-culture
and by per-patient analysis.
• Increasingly detailed chart documentation sur-
rounding antimicrobial regimens was observed after
ASP, which may enhance patient safety.
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